A novel single-cell FISH-flow assay identifies effector memory CD4+ T cells as a major niche for HIV-1 transcription in HIV-infected patients

mBio

Volumn 8, Issue 4, 2017, Pages

  Grau Expósito, Judith ^a   Serra Peinado, Carla ^a   Miguel, Lucia ^a   Navarro, Jordi ^a   Curran, Adrià ^a   Burgos, Joaquin ^a   Ocaña, Imma ^a   Ribera, Esteban ^a   Torrella, Ariadna ^a   Planas, Bibiana ^a   Badía, Rosa ^a   Castellví, Josep ^b   Falcó, Vicenç ^a   Crespo, Manuel ^a,c   Buzon, Maria J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

Author keywords

Human immunodeficiency virus; Viral persistence; Viral reactivation; Viral reservoirs

Indexed keywords

CD32 ANTIGEN; VIRUS RNA; FC RECEPTOR;

ARTICLE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; EFFECTOR CELL; EX VIVO STUDY; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; INTRACELLULAR MEMBRANE; MEMORY T LYMPHOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RNA TRANSCRIPTION; T LYMPHOCYTE SUBPOPULATION; UPREGULATION; VALIDATION PROCESS; VIRUS LOAD; VIRUS REACTIVATION; VIRUS TRANSCRIPTION; ADULT; GENETIC TRANSCRIPTION; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MIDDLE AGED; MONONUCLEAR CELL; PHYSIOLOGY; PROCEDURES; SINGLE CELL ANALYSIS; ULTRASTRUCTURE; VIROLOGY; VIRUS LATENCY;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; FLOW CYTOMETRY; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKOCYTES, MONONUCLEAR; MIDDLE AGED; RECEPTORS, IGG; RNA, VIRAL; SINGLE-CELL ANALYSIS; TRANSCRIPTION, GENETIC; VIRAL LOAD; VIRUS LATENCY;

EID: 85029230568     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00876-17     Document Type: Article

References (62)

1. Siliciano RF, Greene WC. 2011. HIV latency. Cold Spring Harb Perspect Med 1:a007096. https://doi.org/10.1101/cshperspect.a007096.
2. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. 1998. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A 95:8869–8873. https://doi.org/10.1073/pnas.95.15.8869.
3. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, Kempf DJ, Mellors JW, Coffin JM, King MS. 2008. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 105:3879-3884. https://doi.org/10.1073/pnas.0800050105.
4. Chun TW, Justement JS, Murray D, Hallahan CW, Maenza J, Collier AC, Sheth PM, Kaul R, Ostrowski M, Moir S, Kovacs C, Fauci AS. 2010. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 24: 2803–2808. https://doi.org/10.1097/QAD.0b013e328340a239.
5. Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291–1295. https://doi.org/10.1126/science.278.5341.1291.
6. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 94:13193–13197. https://doi.org/10.1073/pnas.94.24.13193.
7. Martinez-Picado J, Deeks SG. 2016. Persistent HIV-1 replication during antiretroviral therapy. Curr Opin HIV AIDS 11:417-423. https://doi.org/10.1097/COH.0000000000000287.
8. Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, Milo R, Baltimore D. 2011. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 477:95–98. https://doi.org/10.1038/nature10347.
9. Fletcher CV, Staskus K, Wietgrefe SW, Rothenberger M, Reilly C, Chipman JG, Beilman GJ, Khoruts A, Thorkelson A, Schmidt TE, Anderson J, Perkey K, Stevenson M, Perelson AS, Douek DC, Haase AT, Schacker TW. 2014. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A 111: 2307–2312. https://doi.org/10.1073/pnas.1318249111.
10. Lorenzo-Redondo R, Fryer HR, Bedford T, Kim EY, Archer J, Kosakovsky Pond SL, Chung YS, Penugonda S, Chipman JG, Fletcher CV, Schacker TW, Malim MH, Rambaut A, Haase AT, McLean AR, Wolinsky SM. 2016. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature 530:51–56. https://doi.org/10.1038/nature16933.
11. Descours B, Petitjean G, López-Zaragoza JL, Bruel T, Raffel R, Psomas C, Reynes J, Lacabaratz C, Levy Y, Schwartz O, Lelievre JD, Benkirane M. 2017. CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses. Nature 543:564-567. https://doi.org/10.1038/nature21710.
12. + T cells. Nat Med 9:727–728. https://doi.org/10.1038/nm880.
13. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, Lai J, Blankson JN, Siliciano JD, Siliciano RF. 2013. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155:540-551. https://doi.org/10.1016/j.cell.2013.09.020.
14. Lewin SR, Rouzioux C. 2011. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS 25:885-897. https://doi.org/10.1097/QAD.0b013e3283467041.
15. Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, Winckelmann A, Palmer S, Dinarello C, Buzon M, Lichterfeld M, Lewin SR, Østergaard L, Søgaard OS. 2014. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 1:e13-e21. https://doi.org/10.1016/S2352-3018(14)70014-1.
16. Leth S, Schleimann MH, Nissen SK, Højen JF, Olesen R, Graversen ME, Jørgensen S, Kjær AS, Denton PW, Mørk A, Sommerfelt MA, Krogsgaard K, Østergaard L, Rasmussen TA, Tolstrup M, Søgaard OS. 2016. Combined effect of Vacc-4x, recombinant human granulocyte macrophage colonystimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial. Lancet HIV 3:e463-e472. https://doi.org/10.1016/S2352-3018(16)30055-8.
17. Kiselinova M, De Spiegelaere W, Buzon MJ, Malatinkova E, Lichterfeld M, Vandekerckhove L. 2016. Integrated and total HIV-1 DNA predict ex vivo viral outgrowth. PLoS Pathog 12:e1005472. https://doi.org/10.1371/journal.ppat.1005472.
18. Buzon MJ, Martin-Gayo E, Pereyra F, Ouyang Z, Sun H, Li JZ, Piovoso M, Shaw A, Dalmau J, Zangger N, Martinez-Picado J, Zurakowski R, Yu XG, Telenti A, Walker BD, Rosenberg ES, Lichterfeld M. 2014. Longterm antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. J Virol 88:10056-10065. https://doi.org/10.1128/JVI.01046-14.
19. Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, Bosch RJ, Lai J, Chioma S, Emad F, Abdel-Mohsen M, Hoh R, Hecht F, Hunt P, Somsouk M, Wong J, Johnston R, Siliciano RF, Richman DD, O’Doherty U, Palmer S, Deeks SG, Siliciano JD. 2013. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 9:e1003174. https://doi.org/10.1371/journal.ppat.1003174.
20. Williams JP, Hurst J, Stöhr W, Robinson N, Brown H, Fisher M, Kinloch S, Cooper D, Schechter M, Tambussi G, Fidler S, Carrington M, Babiker A, Weber J, Koelsch KK, Kelleher AD, Phillips RE, Frater J, SPARTACTrial Investigators. 2014. HIV-1 DNA predicts disease progression and posttreatment virological control. eLife 3:e03821. https://doi.org/10.7554/eLife.03821.
21. Azzoni L, Foulkes AS, Papasavvas E, Mexas AM, Lynn KM, Mounzer K, Tebas P, Jacobson JM, Frank I, Busch MP, Deeks SG, Carrington M, O’Doherty U, Kostman J, Montaner LJ. 2013. Pegylated interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis 207:213–222. https://doi.org/10.1093/infdis/jis663.
22. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sékaly RP. 2009. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15:893–900. https://doi.org/10.1038/nm.1972.
23. Buzon MJ, Sun H, Li C, Shaw A, Seiss K, Ouyang Z, Martin-Gayo E, Leng J, Henrich TJ, Li JZ, Pereyra F, Zurakowski R, Walker BD, Rosenberg ES, Yu XG, Lichterfeld M. 2014. HIV-1 persistence in CD4_ T cells with stem cell-like properties. Nat Med 20:139-142. https://doi.org/10.1038/nm.3445.
24. Perreau M, Savoye AL, De Crignis E, Corpataux JM, Cubas R, Haddad EK, De Leval L, Graziosi C, Pantaleo G. 2013. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med 210:143–156. https://doi.org/10.1084/jem.20121932.
25. Puertas MC, Noguera-Julian M, Massanella M, Pou C, Buzon MJ, Clotet B, Stevenson M, Paredes R, Blanco J, Martinez-Picado J. 2016. Lack of concordance between residual viremia and viral variants driving de novo infection of CD4(_) T cells on ART. Retrovirology 13:51. https://doi.org/10.1186/s12977-016-0282-9.
26. Pasternak AO, Lukashov VV, Berkhout B. 2013. Cell-associated HIV RNA: a dynamic biomarker of viral persistence. Retrovirology 10:41. https://doi.org/10.1186/1742-4690-10-41.
27. + T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci U S A 100:1908-1913. https://doi.org/10.1073/pnas.0437640100.
28. + T cells. PLoS Pathog 2:e68. https://doi.org/10.1371/journal.ppat.0020068.
29. Procopio FA, Fromentin R, Kulpa DA, Brehm JH, Bebin AG, Strain MC, Richman DD, O’Doherty U, Palmer S, Hecht FM, Hoh R, Barnard RJ, Miller MD, Hazuda DJ, Deeks SG, Sékaly RP, Chomont N. 2015. A novel assay to measure the magnitude of the inducible viral reservoir in HIV-infected individuals. EBioMedicine 2:874–883. https://doi.org/10.1016/j.ebiom.2015.06.019.
30. Saksela K, Stevens CE, Rubinstein P, Taylor PE, Baltimore D. 1995. HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker of risk for progression to AIDS. Ann Intern Med 123:641-648. https://doi.org/10.7326/0003-4819-123-9-199511010-00001.
31. Pasternak AO, Jurriaans S, Bakker M, Berkhout B, Lukashov VV. 2010. Steady increase in cellular HIV-1 load during the asymptomatic phase of untreated infection despite stable plasma viremia. AIDS 24:1641–1649. https://doi.org/10.1097/QAD.0b013e32833b3171.
32. + T-cell number decline in human immunodeficiency virus type 1-infected individuals. J Virol 69:2092–2100.
33. Saltarelli MJ, Hadziyannis E, Hart CE, Harrison JV, Felber BK, Spira TJ, Pavlakis GN. 1996. Analysis of human immunodeficiency virus type 1 mRNA splicing patterns during disease progression in peripheral blood mononuclear cells from infected individuals. AIDS Res Hum Retroviruses 12:1443–1456. https://doi.org/10.1089/aid.1996.12.1443.
34. Iglesias-Ussel MD, Romerio F. 2011. HIVreservoirs:thenewfrontier. AIDSRev 13:13–29.
35. Fischer M, Joos B, Niederöst B, Kaiser P, Hafner R, von Wyl V, Ackermann M, Weber R, Günthard HF. 2008. Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy. Retrovirology 5:107. https://doi.org/10.1186/1742-4690-5-107.
36. Kaiser P, Joos B, Niederöst B, Weber R, Günthard HF, Fischer M. 2007. Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes. J Virol 81:9693–9706. https://doi.org/10.1128/JVI.00492-07.
37. Deleage C, Wietgrefe SW, Del Prete G, Morcock DR, Hao XP, Piatak M, Jr, Bess J, Anderson JL, Perkey KE, Reilly C, McCune JM, Haase AT, Lifson JD, Schacker TW, Estes JD. 2016. Defining HIV and SIV reservoirs in lymphoid tissues. Pathog Immun 1:68-106. https://doi.org/10.20411/pai.v1i1.100.
38. Kimura T, Nishikawa M, Ohyama A. 1994. Intracellular membrane traffic of human immunodeficiency virus type 1 envelope glycoproteins: vpu liberates Golgi-targeted gp160 from CD4-dependent retention in the endoplasmic reticulum. J Biochem 115:1010-1020. https://doi.org/10.1093/oxfordjournals.jbchem.a124414.
39. Garcia JV, Miller AD. 1991. Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 350:508-511. https://doi.org/10.1038/350508a0.
40. Fischer M, Joos B, Hirschel B, Bleiber G, Weber R, Günthard HF, Swiss HIV Cohort Study. 2004. Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef. J Infect Dis 190:1979-1988. https://doi.org/10.1086/425983.
41. Pomerantz RJ, Seshamma T, Trono D. 1992. Efficient replication of human immunodeficiency virus type 1 requires a threshold level of Rev: potential implications for latency. J Virol 66:1809-1813.
42. Izquierdo-Useros N, Naranjo-Gómez M, Archer J, Hatch SC, Erkizia I, Blanco J, Borràs FE, Puertas MC, Connor JH, Fernández-Figueras MT, Moore L, Clotet B, Gummuluru S, Martinez-Picado J. 2009. Capture and transfer of HIV-1 particles by mature dendritic cells converges with the exosome-dissemination pathway. Blood 113:2732–2741. https://doi.org/10.1182/blood-2008-05-158642.
43. Zhu T, Muthui D, Holte S, Nickle D, Feng F, Brodie S, Hwangbo Y, Mullins JI, Corey L. 2002. Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(-) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J Virol 76:707–716. https://doi.org/10.1128/JVI.76.2.707-716.2002.
44. Marodon G, Warren D, Filomio MC, Posnett DN. 1999. Productive infection of double-negative T cells with HIV in vivo. Proc Natl Acad Sci U S A 96:11958-11963. https://doi.org/10.1073/pnas.96.21.11958.
45. Yukl SA, Shergill AK, Ho T, Killian M, Girling V, Epling L, Li P, Wong LK, Crouch P, Deeks SG, Havlir DV, McQuaid K, Sinclair E, Wong JK. 2013. The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence. J Infect Dis 208:1212–1220. https://doi.org/10.1093/infdis/jit308.
46. Herbein G, Van Lint C, Lovett JL, Verdin E. 1998. Distinct mechanisms trigger apoptosis in human immunodeficiency virus type 1-infected and in uninfected bystander T lymphocytes. J Virol 72:660–670.
47. Fischer M, Günthard HF, Opravil M, Joos B, Huber W, Bisset LR, Ott P, Böni J, Weber R, Cone RW. 2000. Residual HIV-RNA levels persist for up to 2.5 years in peripheral blood mononuclear cells of patients on potent antiretroviral therapy. AIDS Res Hum Retroviruses 16:1135–1140. https://doi.org/10.1089/088922200414974.
48. Pasternak AO, Jurriaans S, Bakker M, Prins JM, Berkhout B, Lukashov VV. 2009. Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PLoS One 4:e8490. https://doi.org/10.1371/journal.pone.0008490.
49. Kiselinova M, Geretti AM, Malatinkova E, Vervisch K, Beloukas A, Messiaen P, Bonczkowski P, Trypsteen W, Callens S, Verhofstede C, De Spiegelaere W, Vandekerckhove L. 2015. HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapinebased regimens. J Antimicrob Chemother 70:3311–3316. https://doi.org/10.1093/jac/dkv250.
50. Haase AT, Henry K, Zupancic M, Sedgewick G, Faust RA, Melroe H, Cavert W, Gebhard K, Staskus K, Zhang ZQ, Dailey PJ, Balfour HH, Jr, Erice A, Perelson AS. 1996. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 274:985–989. https://doi.org/10.1126/science.274.5289.985.
51. Cavert W, Notermans DW, Staskus K, Wietgrefe SW, Zupancic M, Gebhard K, Henry K, Zhang ZQ, Mills R, McDade H, Schuwirth CM, Goudsmit J, Danner SA, Haase AT. 1997. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276:960-964. https://doi.org/10.1126/science.276.5314.960.
52. Masopust D, Schenkel JM. 2013. The integration of T cell migration, differentiation and function. Nat Rev Immunol 13:309-320. https://doi.org/10.1038/nri3442.
53. Mahnke YD, Brodie TM, Sallusto F, Roederer M, Lugli E. 2013. The who’s who of T-cell differentiation: human memory T-cell subsets. Eur J Immunol 43:2797–2809. https://doi.org/10.1002/eji.201343751.
54. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. 2012. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487:482-485. https://doi.org/10.1038/nature11286.
55. Martrus G, Niehrs A, Cornelis R, Rechtien A, García-Beltran W, Lütgehetmann M, Hoffmann C, Altfeld M. 2016. Kinetics of HIV-1 latency reversal quantified on the single-cell level using a novel flow-based technique. J Virol 90:9018-9028. https://doi.org/10.1128/JVI.01448-16.
56. Baxter AE, Niessl J, Fromentin R, Richard J, Porichis F, Charlebois R, Massanella M, Brassard N, Alsahafi N, Delgado GG, Routy JP, Walker BD, Finzi A, Chomont N, Kaufmann DE. 2016. Single-cell characterization of viral translation-competent reservoirs in HIV-Infected individuals. Cell Host Microbe 20:368-380. https://doi.org/10.1016/j.chom.2016.07.015.
57. Laird GM, Bullen CK, Rosenbloom DI, Martin AR, Hill AL, Durand CM, Siliciano JD, Siliciano RF. 2015. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest 125:1901–1912. https://doi.org/10.1172/JCI80142.
58. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. 2014. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 20:425-429. https://doi.org/10.1038/nm.3489.
59. Jordan A, Bisgrove D, Verdin E. 2003. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 22: 1868–1877. https://doi.org/10.1093/emboj/cdg188.
60. Baba M, Miyake H, Okamoto M, Iizawa Y, Okonogi K. 2000. Establishment of a CCR5-expressing T-lymphoblastoid cell line highly susceptible to R5 HIV type 1. AIDS Res Hum Retroviruses 16:935–941. https://doi.org/10.1089/08892220050058344.
61. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, Decker JM, Li Y, Salazar MG, Polonis VR, Mlisana K, Karim SA, Hong K, Greene KM, Bilska M, Zhou J, Allen S, Chomba E, Mulenga J, Vwalika C, Gao F, Zhang M, Korber BT, Hunter E, Hahn BH, Montefiori DC. 2006. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in southern Africa. J Virol 80:11776-11790. https://doi.org/10.1128/JVI.01730-06.
62. Hu Y, Smyth GK. 2009. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 347:70-78. https://doi.org/10.1016/j.jim.2009.06.008.